Program directory
Off-Label Longevity Prescribing
Rapamycin, metformin, GLP-1 drugs, and similar approved medications prescribed for aging rather than for the conditions on their labels. The program type with the most interesting early human data and the least room for carelessness.
| Focus | Prescription model |
|---|---|
| What It Covers |
|
| Typical Cost | $100 to $400 per month including visits |
| Evidence Level | Early: one randomized year-long safety trial of low-dose rapamycin in healthy adults (PEARL, 115 participants) found it generally well tolerated with modest signals in women; the metformin aging trial has not completed; GLP-1 outcome data apply to obesity and diabetes, not healthy-weight adults |
| Regulatory Status | FDA-approved drugs prescribed off-label; no drug is approved to treat aging |
| Watchouts |
|
| Questions To Ask |
|
Parallel Coverage
Related Resources
This profile connects back into the article, glossary, and FAQ layers so overlapping coverage stays discoverable instead of fragmented.
Article
What Is Longevity Medicine?
How longevity medicine differs from conventional healthcare, what it typically involves, and where the evidence stands.
ArticleThe Hallmarks of Aging
A guide to the biological processes researchers believe drive aging at the cellular level, and why they matter for longevity science.
ArticleFasting and Longevity Research
What research on caloric restriction, time-restricted eating, and intermittent fasting actually shows about healthspan.